Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Galenea, CHDI Foundation form Huntington’s collaboration
October 2011
SHARING OPTIONS:

CAMBRIDGE, Mass.—Galenea Corp. and CHDI Foundation Inc. have come together to collaborate on the identification of synaptic dysfunctions linked to Huntington's disease (HD) using Galenea's proprietary synaptic transmission drug discovery platform. Galenea's platform, which examines synaptic transmission on several levels, will hopefully offer insight into a new approach to discovering therapies for HD. The company's Multiwell Automated Neuro TRansmission Assay (MANTRA) system is a high-throughput screening assay that monitors synaptic events at the cellular level through the use of primary neuronal cultures. Galenea's system for establishing in-vivo EEG measures of behaviors in rodent disease models by monitoring brain and behavioral activities in parallel also allows for surveillance at the network level. The collaboration's two-pronged approach will aid in the identification and characterization of synaptic defects caused by HD at the neuronal and network levels.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.